BENIGN HEPATOCELLULAR TUMORS - MRI AFTER SUPERPARAMAGNETIC IRON-OXIDE ADMINISTRATION

被引：66

作者：

GRANDIN, C

VANBEERS, BE

ROBERT, A

GIGOT, JF

GEUBEL, A

PRINGOT, J

机构：

[1] CLIN UNIV ST LUC,DEPT SURG,B-1200 BRUSSELS,BELGIUM

[2] CLIN UNIV ST LUC,DEPT INTERNAL MED,GASTROENTEROL SECT,B-1200 BRUSSELS,BELGIUM

[3] UNIV CATHOLIQUE LOUVAIN,INST STAT,BRUSSELS,BELGIUM

来源：

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY | 1995年 / 19卷 / 03期

关键词：

LIVER; NEOPLASMS; IRON; MAGNETIC RESONANCE IMAGING; TISSUE CHARACTERIZATION;

D O I：

10.1097/00004728-199505000-00014

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Objective: Our goal was to describe the features of benign hepatocellular tumors on superparamagnetic iron oxide (SPIO)-enhanced MR images and to evaluate the potential role of SPIO administration in the diagnosis of these tumors. Materials and Methods: The T1- and T2-weighted SE images were performed before and after SPIO administration in 19 patients with focal nodular hyperplasia (FNH) or adenomas. The lesions were counted and qualitatively assessed. In 32 tumors with a diameter of >10 mm, the contrast-to-noise ratio (CNR) and the liver and tumor enhancement were calculated. Results: Thirty-seven tumors were detected on MR images: 29 before and 36 after SPIO administration (p < 0.05). The SPIO-enhanced T1-weighted images provided the highest detection rate and CNR. The central scar was most conspicuous on SPIO-enhanced T2-weighted images. Most FNHs and adenomas lost less signal than the liver, three tumors did not lose signal, and four FNHs showed a signal loss equal to or greater than that of the liver. Conclusion: The SPIO-enhanced T1-weighted images increased the CNR and the detection rate of benign hepatocellular tumors. On T2-weighted images, most benign hepatocellular tumors showed a signal decrease after SPIO administration. No significant difference in signal loss was observed between FNH and adenomas.

引用

页码：412 / 418

页数：7

共 25 条

[1] Wisse E., Doucet D., Van Bossuyt H., A transmission electron microscopic study on the uptake of AMI-25 by sinusoidal liver cells, Cells of the Hepatic Sinusoid, 3, pp. 534-539, (1991)
[2] Weissleder R., Stark D.D., Engelstad B.L., Et al., Superparamagnetic iron oxide: Pharmacokinetics and toxicity, AJR, 152, pp. 167-173, (1989)
[3] Van Hecke P., Marchal G., Decrop E., Baert A.L., Experimental study of the pharmacokinetics and dose response of ferrite particles used as a contrast agent in MR1 of the normal liver of the rabbit, Invest Radiol, 24, pp. 397-399, (1989)
[4] Kawamori Y., Matsui O., Kadoya M., Yoshikawa J., Demachi H., Takashima T., Differentiation of hepatocellular carcinomas from hyperplastic nodules induced in rat liver with ferrite-enhanced MR imaging, Radiology, 183, pp. 65-72, (1992)
[5] Ferrucci J.T., Stark D.D., Iron oxide-enhanced MR imaging of the liver and spleen: Review of the first 5 years, AJR, 155, pp. 943-950, (1990)
[6] Kawamura Y., Endo K., Watanabe Y., Et al., Use of magnetite particles as a contrast agent for MR imaging of the liver, Radiology, 174, pp. 357-360, (1990)
[7] Tsang Y.M., Stark D.D., Chia-Mei Chen M., Weissleder R., Wittenberg J., Ferruci J.T., Hepatic micrometastases in the rat: Ferrite-enhanced MR imaging, Radiology, 167, pp. 21-24, (1988)
[8] Fretz C.J., Stark D.D., Metz C.E., Et al., Detection of hepatic metastases: Comparison of contrast-enhanced CT, unenhanced MR imaging, and iron oxide-enhanced MR imaging, AJR, 155, pp. 763-770, (1990)
[9] Winter T.C., Freeny P.C., Nghiem H.V., Et al., MR imaging with IV superparamagnetic iron oxide: Efficacy in the detection of focal hepatic lesions, AJR, 161, pp. 1191-1198, (1993)
[10] Salvo A.F., Schiller A., Athanasoulis C., Galdabini J., McKusick K.A., Hepatoadenoma and focal nodular hyperplasia: Pitfalls in radiocolloid imaging, Radiology, 125, pp. 451-455, (1977)

← 1 2 3 →